Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyp... Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.4 | 22.4299065421 | 10.7 | 14.49 | 10.25 | 201678 | 11.24482856 | CS |
| 4 | 3.19 | 32.1897073663 | 9.91 | 14.49 | 9.88 | 159545 | 11.5712012 | CS |
| 12 | 2.39 | 22.3155929038 | 10.71 | 15.555 | 9.12 | 144407 | 12.15088715 | CS |
| 26 | 5.05 | 62.7329192547 | 8.05 | 15.555 | 7.715 | 192323 | 11.45827558 | CS |
| 52 | 0.57 | 4.54908220271 | 12.53 | 55.89 | 5.2044 | 268886 | 16.38680837 | CS |
| 156 | 0.1 | 0.769230769231 | 13 | 98 | 5.2044 | 155381 | 24.22429519 | CS |
| 260 | 0.1 | 0.769230769231 | 13 | 98 | 5.2044 | 155381 | 24.22429519 | CS |
02opida
9月前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。